Alfaidi, M., Barker, R.A., Kuan, W.L. An update on immune-based alpha-synuclein trials in Parkinson's disease. J. Neurol., 272: 21, 2024; doi: 10.1007/s00415-024-12770-x
Amin, J., Erskine, D., Donaghy, P.C., Surendranathan, A., Swann, P., Kunicki, A.P., Boche, D., Holmes, C., McKeith, I.G., O'Brien, J.T., Teeling, J.L., Thomas, A.J. Inflammation in dementia with Lewy bodies. Neurobiol. Dis., 168:105698, 2022; doi: 10.1016/j.nbd.2022.105698
Borsche, M., Pereira, S.L., Klein, C., Grünewald, A. Mitochondria and Parkinson's disease: clinical, molecular, and translational aspects. J. Parkinsons Dis., 11: 45-60, 2021; doi: 10.3233/JPD-201981
Boström, E., Bachhav, S.S., Xiong, H., Zadikoff, C., Li, Q., Cohen, E., Dreher, I., Torrång, A., Osswald, G., Moge, M., Appelkvist, P., Fälting, J., Odergren, T. Safety, tolerability, and pharmacokinetics of single doses of exidavnemab (BAN0805), an anti-α-synuclein antibody, in healthy Western, Caucasian, Japanese, and Han Chinese adults. J. Clin. Pharmacol., 64: 1432-1442, 2024; doi: 10.1002/jcph.6103
Bourdenx, M., Dovero, S., Engeln, M., Bido, S., Bastide, M.F., Dutheil, N., Vollenweider, I., Baud, L., Piron, C., Grouthier, V., Boraud, T., Porras, G., Li, Q., Baekelandt, V., Scheller, D., Michel, A., Fernagut, P.O., Georges, F., Courtine, G., Bezard, E., Dehay, B. Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression. Acta Neuropathol. Commun., 3: 46, 2015; doi: 10.1186/s40478-015-0222-2
Braak, H., Del Tredici, K., Rüb, U., de Vos, R.A., Jansen Steur, E.N., Braak, E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging., 24: 197-211, 2003; doi: 10.1016/s0197-4580(02)00065-9
Brice, N.L., Carlton, M., Margolin, D.H., Bexon, M., Matthews, K.L., Dawson, L.A., Ellenbogen, A.L., Olanow, C.W., Dubow, J., Kieburtz, K. CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations: a double-blind, randomized, phase 2 trial. EClinicalMedicine, 77: 102882, 2024; doi: 10.1016/j.eclinm.2024.102882
Brochard, V., Combadière, B., Prigent, A., Laouar, Y., Perrin, A., Beray-Berthat, V., Bonduelle, O., Alvarez-Fischer, D., Callebert, J., Launay, J.M., Duyckaerts, C., Flavell, R.A., Hirsch, E.C., Hunot, S. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest., 119: 182-92, 2009; doi: 10.1172/JCI36470
Calabresi, P., Mechelli, A., Natale, G., Volpicelli-Daley, L., Di Lazzaro, G., Ghiglieri, V. Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis., 14: 176, 2023; doi: 10.1038/s41419-023-05672-9
Chatterjee, D., Kordower, J.H. Immunotherapy in Parkinson's disease: current status and future directions. Neurobiol. Dis., 132: 104587, 2019; doi: 10.1016/j.nbd.2019.104587
Chen, K., Wang, H., Ilyas, I., Mahmood, A., Hou, L. Microglia and astrocytes dysfunction and key neuroinflammation-based biomarkers in Parkinson's disease. Brain Sci., 13: 634, 2023; doi: 10.3390/brainsci13040634
Daher, J.P., Abdelmotilib, H.A., Hu, X., Volpicelli-Daley, L.A., Moehle, M.S., Fraser, K.B., Needle, E., Chen, Y., Steyn, S.J., Galatsis, P., Hirst, W.D., West, A.B. Leucine-rich repeat kinase 2 (LRRK2) pharmacological inhibition abates α-synuclein gene-induced neurodegeneration. J. Biol. Chem., 290: 19433-44, 2015; doi: 10.1074/jbc.M115.660001
Daher, J.P., Volpicelli-Daley, L.A., Blackburn, J.P., Moehle, M.S., West, A.B. Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats. Proc. Natl. Acad. Sci. U. S. A., 111: 9289-94, 2014; doi: 10.1073/pnas.1403215111
Deyell, J.S., Sriparna, M., Ying, M., Mao, X. The interplay between α-synuclein and microglia in α-synucleinopathies. Int. J. Mol. Sci., 24: 2477, 2023; doi: 10.3390/ijms24032477
Dong-Chen, X., Yong, C., Yang, X., Chen-Yu, S., Li-Hua, P. Signaling pathways in Parkinson's disease: molecular mechanisms and therapeutic interventions. Signal Transduct. Target Ther., 8: 73, 2023; doi: 10.1038/s41392-023-01353-3
Dovonou, A., Bolduc, C., Soto Linan, V., Gora, C., Peralta Iii, M.R., Lévesque, M. Animal models of Parkinson's disease: bridging the gap between disease hallmarks and research questions. Transl. Neurodegener., 12: 36, 2023; doi: 10.1186/s40035-023-00368-8
Edison, P., Ahmed, I., Fan, Z., Hinz, R., Gelosa, G., Ray Chaudhuri, K., Walker, Z., Turkheimer, F.E., Brooks, D.J. Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia. Neuropsychopharmacology, 38: 938-49, 2013; doi: 10.1038/npp.2012.255
Edwards, T.L., Scott, W.K., Almonte, C., Burt, A., Powell, E.H., Beecham, G.W., Wang, L., Züchner, S., Konidari, I., Wang, G., Singer, C., Nahab, F., Scott, B., Stajich, J.M., Pericak-Vance, M., Haines, J., Vance, J.M., Martin, E.R. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann. Hum. Genet., 74: 97-109, 2010; doi: 10.1111/j.1469-1809.2009.00560.x
Eijsvogel, P., Misra, P., Concha-Marambio, L., Boyd, J.D., Ding, S., Fedor, L., Hsieh, Y.T., Sun, Y.S., Vroom, M.M., Farris, C.M., Ma, Y., de Kam, M.L., Radanovic, I., Vissers, M.F.J.M., Mirski, D., Shareghi, G., Shahnawaz, M., Singer, W., Kremer, P., Groeneveld, G.J., Yu, H.J., Dodart, J.C. Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial. Nat. Med., 30: 2631-2640, 2024; doi: 10.1038/s41591-024-03101-8
Feng, Y., Zheng, C., Zhang, Y., Xing, C., Cai, W., Li, R., Chen, J., Duan, Y. Triptolide inhibits preformed fibril-induced microglial activation by targeting the microRNA155-5p/SHIP1 pathway. Oxid. Med. Cell Longev., 2019: 6527638, 2019; doi: 10.1155/2019/6527638
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R.B., Brooks, D.J. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis., 21: 404-12, 2006; doi: 10.1016/j.nbd.2005.08.002
Gordon, R., Albornoz, E.A., Christie, D.C., Langley, M.R., Kumar, V., Mantovani, S., Robertson, A.A.B., Butler, M.S., Rowe, D.B., O'Neill, L.A., Kanthasamy, A.G., Schroder, K., Cooper, M.A., Woodruff, T.M. Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice. Sci. Transl. Med., 10: eaah4066. doi: 10.1126/scitranslmed.aah4066
Grotemeyer, A., Fischer, J.F., Koprich, J.B., Brotchie, J.M., Blum, R., Volkmann, J., Ip, C.W. Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson's disease. J. Neuroinflammation., 20: 79, 2023; doi: 10.1186/s12974-023-02759-0
Grünewald, A., Kumar, K.R., Sue, C.M. New insights into the complex role of mitochondria in Parkinson's disease. Prog. Neurobiol., 177: 73-93, 2019; doi: 10.1016/j.pneurobio.2018.09.003
Hong, B., Ohtake, Y., Itokazu, T., Yamashita, T. Glial senescence enhances α-synuclein pathology owing to its insufficient clearance caused by autophagy dysfunction. Cell Death Discov., 10: 50, 2024; doi: 10.1038/s41420-024-01816-8
Houser, M.C., Tansey, M.G. The gut-brain axis: is intestinal inflammation a silent driver of Parkinson's disease pathogenesis? NPJ Parkinsons Dis., 3: 3, 2017; doi: 10.1038/s41531-016-0002-0
Huang, W., Lv, Q., Xiao, Y., Zhong, Z., Hu, B., Yan, S., Yan, Y., Zhang, J., Shi, T., Jiang, L., Li, W., Lu, G. Triggering receptor expressed on myeloid cells 2 protects dopaminergic neurons by promoting autophagy in the inflammatory pathogenesis of Parkinson's disease. Front. Neurosci., 15: 745815, 2021; doi: 10.3389/fnins.2021.745815
Huang, P., Zhang, Z., Zhang, P., Feng, J., Xie, J., Zheng, Y., Liang, X., Zhu, B., Chen, Z., Feng, S., Wang, L., Lu, J., Liu, Y., Zhang, Y. TREM2 deficiency aggravates NLRP3 inflammasome activation and pyroptosis in MPTP-induced Parkinson's disease mice and LPS-induced BV2 cells. Mol. Neurobiol., 61: 2590-2605, 2024; doi: 10.1007/s12035-023-03713-0
Jankovic, J., Goodman, I., Safirstein, B., Marmon, T.K., Schenk, D.B., Koller, M., Zago, W., Ness, D.K., Griffith, S.G., Grundman, M., Soto, J., Ostrowitzki, S., Boess, F.G., Martin-Facklam, M., Quinn, J.F., Isaacson, S.H., Omidvar, O., Ellenbogen, A., Kinney, G.G. Safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti-α-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial. JAMA Neurol., 75: 1206-1214, 2018; doi: 10.1001/jamaneurol.2018.1487
Jeon, Y.M., Kwon, Y., Jo, M., Lee, S., Kim, S., Kim, H.J. The role of glial mitochondria in α-synuclein toxicity. Front. Cell Dev. Biol., 8: 548283, 2020; doi: 10.3389/fcell.2020.548283
Karpenko, M.N., Vasilishina, A.A., Gromova, E.A., Muruzheva, Z.M., Miliukhina, I.V., Bernadotte, A. Interleukin-1β, interleukin-1 receptor antagonist, interleukin-6, interleukin-10, and tumor necrosis factor-α levels in CSF and serum in relation to the clinical diversity of Parkinson's disease. Cell Immunol., 327: 77-82, 2018; doi: 10.1016/j.cellimm.2018.02.011
Lang, A.E., Siderowf, A.D., Macklin, E.A., Poewe, W., Brooks, D.J., Fernandez, H.H., Rascol, O., Giladi, N., Stocchi, F., Tanner, C.M., Postuma, R.B., Simon, D.K., Tolosa, E., Mollenhauer, B., Cedarbaum, J.M., Fraser, K., Xiao, J., Evans, K.C., Graham, D.L., Sapir, I., Inra, J., Hutchison, R.M., Yang, M., Fox, T., Budd Haeberlein, S., Dam, T.; SPARK Investigators. Trial of cinpanemab in early Parkinson's disease. N. Engl. J. Med., 387: 408-420, 2022; doi: 10.1056/NEJMoa2203395
Lee, E., Hwang, I., Park, S., Hong, S., Hwang, B., Cho, Y., Son, J., Yu, J.W. MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration. Cell Death Differ., 26: 213-228, 2019; doi: 10.1038/s41418-018-0124-5
Li, Y., Xia, Y., Yin, S., Wan, F., Hu, J., Kou, L., Sun, Y., Wu, J., Zhou, Q., Huang, J., Xiong, N., Wang, T. Targeting microglial α-synuclein/TLRs/NF-kappaB/NLRP3 inflammasome axis in Parkinson's disease. Front. Immunol., 12: 719807, 2021; doi: 10.3389/fimmu.2021.719807
Lundblad, M., Decressac, M., Mattsson, B., Björklund, A. Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons. Proc. Natl. Acad. Sci. U. S. A., 109: 3213-9, 2012; doi: 10.1073/pnas.1200575109
Niskanen, J., Peltonen, S., Ohtonen, S., Fazaludeen, M.F., Luk, K.C., Giudice, L., Koistinaho, J., Malm, T., Goldsteins, G., Albert, K., Lehtonen, Š. Uptake of alpha-synuclein preformed fibrils is suppressed by inflammation and induces an aberrant phenotype in human microglia. Glia, 73: 159-174, 2025; doi: 10.1002/glia.24626
Ou, Z., Zhou, Y., Wang, L., Xue, L., Zheng, J., Chen, L., Tong, Q. NLRP3 inflammasome inhibition prevents α-synuclein pathology by relieving autophagy dysfunction in chronic MPTP-treated NLRP3 knockout mice. Mol. Neurobiol., 58: 1303-1311, 2021; doi: 10.1007/s12035-020-02198-5
Pagano, G., Taylor, K.I., Anzures-Cabrera, J., Marchesi, M., Simuni, T., Marek, K., Postuma, R.B., Pavese, N., Stocchi, F., Azulay, J.P., Mollenhauer, B., López-Manzanares, L., Russell, D.S., Boyd, J.T., Nicholas, A.P., Luquin, M.R., Hauser, R.A., Gasser, T., Poewe, W., Ricci, B. Boulay, A., Vogt, A., Boess, F.G., Dukart, J., D'Urso, G., Finch, R., Zanigni, S., Monnet, A., Pross, N., Hahn, A., Svoboda, H., Britschgi, M., Lipsmeier, F., Volkova-Volkmar, E., Lindemann, M., Dziadek, S., Holiga, Š., Rukina, D., Kustermann, T., Kerchner, G.A., Fontoura, P., Umbricht, D., Doody, R., Nikolcheva, T., Bonni, A., PASADENA Investigators, Prasinezumab Study Group. Trial of prasinezumab in early-stage Parkinson's disease. N. Engl. J. Med., 387: 421-432, 2022; doi: 10.1056/NEJMoa2202867
Pagano, G., Taylor, K. I., Anzures Cabrera, J., Simuni, T., Marek, K., Postuma, R.B., Pavese, N., Stocchi, F., Brockmann, K., Svoboda, H., Trundell, D., Monnet, A., Doody, R., Fontoura, P., Kerchner, G.A., Brundin, P., Nikolcheva, T., Bonni, A., PASADENA Investigators, Prasinezumab Study Group. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease. Nat. Med., 30: 1096-1103, 2024; doi: 10.1038/s41591-024-02886-y
Parnetti, L., Gaetani, L., Eusebi, P., Paciotti, S., Hansson, O., El-Agnaf, O., Mollenhauer, B., Blennow, K., Calabresi, P. CSF and blood biomarkers for Parkinson's disease. Lancet Neurol., 18: 573-586, 2019; doi: 10.1016/S1474-4422(19)30024-9
Phan, J.A., Stokholm, K., Zareba-Paslawska, J., Jakobsen, S., Vang, K., Gjedde, A., Landau, A.M., Romero-Ramos, M. Early synaptic dysfunction induced by α-synuclein in a rat model of Parkinson's disease. Sci. Rep., 7: 6363, 2017; doi: 10.1038/s41598-017-06724-9
Poewe, W., Seppi, K., Tanner, C.M., Halliday, G.M., Brundin, P., Volkmann, J., Schrag, A.E., Lang, A.E. Parkinson disease. Nat. Rev. Dis. Primers., 3: 17013, 2017; doi: 10.1038/nrdp.2017.13
Poewe, W., Volc, D., Seppi, K., Medori, R., Lührs, P., Kutzelnigg, A., Djamshidian, A., Thun-Hohenstein, C., Meissner, W. G., Rascol, O., Schneeberger, A., Staffler, G., AFF011 investigators, AFF011 study investigators:, Poewe, W., Seppi, K., Djamshidian, A., deMarzi, R., Heim, B., Mangesius, S., Stolz, R., Wachowicz, K., Volc, D., Thun-Hohenstein, C., Riha, C., Schneeberger, A., Bürger, V., Galabova, G. Safety and tolerability of active immunotherapy targeting α-synuclein with PD03A in patients with early Parkinson's disease: a randomized, placebo-controlled, phase 1 study. J. Parkinsons Dis., 11: 1079-1089, 2021; doi: 10.3233/JPD-212594
Saijo, K., Winner, B., Carson, C.T., Collier, J.G., Boyer, L., Rosenfeld, M.G., Gage, F.H., Glass, C.K. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell, 137: 47-59, 2009; doi: 10.1016/j.cell.2009.01.038
Sanchez-Guajardo, V., Febbraro, F., Kirik, D., Romero-Ramos, M. Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS One, 5: e8784, 2010; doi: 10.1371/journal.pone.0008784
Shaerzadeh, F., Phan, L., Miller, D., Dacquel, M., Hachmeister, W., Hansen, C., Bechtle, A., Tu, D., Martcheva, M., Foster, T.C., Kumar, A., Streit, W.J., Khoshbouei, H. Microglia senescence occurs in both substantia nigra and ventral tegmental area. Glia, 68: 2228-2245, 2020; doi: 10.1002/glia.23834
Theodore, S., Cao, S., McLean, P.J., Standaert, D.G. Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J. Neuropathol. Exp. Neurol., 67: 1149-58, 2008; doi: 10.1097/NEN.0b013e31818e5e99
Thomsen, M.B., Ferreira, S.A., Schacht, A.C., Jacobsen, J., Simonsen, M., Betzer, C., Jensen, P.H., Brooks, D.J., Landau, A.M., Romero-Ramos, M. PET imaging reveals early and progressive dopaminergic deficits after intra-striatal injection of preformed alpha-synuclein fibrils in rats. Neurobiol. Dis., 149: 105229, 2021; doi: 10.1016/j.nbd.2020.105229
Ulusoy, A., Decressac, M., Kirik, D., Björklund, A. Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease. Prog. Brain Res., 184: 89-111, 2010; doi: 10.1016/S0079-6123(10)84005-1
Volc, D., Poewe, W., Kutzelnigg, A., Lührs, P., Thun-Hohenstein, C., Schneeberger, A., Galabova, G., Majbour, N., Vaikath, N., El-Agnaf, O., Winter, D., Mihailovska, E., Mairhofer, A., Schwenke, C., Staffler, G., Medori, R. Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial. Lancet Neurol., 19: 591-600, 2020; doi: 10.1016/S1474-4422(20)30136-8
Wang, Q., Yang, S., Zhang, X., Zhang, S., Chen, L., Wang, W., Chen, N., Yan, J. Inflammasomes in neurodegenerative diseases. Transl. Neurodegener., 13: 65, 2024; doi: 10.1186/s40035-024-00459-0
Yao, X.Y., Guan, L.N., Chen, Q., Ren, C. LRRK2 G2019S and Parkinson's disease: insight from neuroinflammation. Postgrad. Med. J., 100: 4-11, 2023; doi: 10.1093/postmj/qgad080
Youssef, P., Hughes, L., Kim, W.S., Halliday, G.M., Lewis, S.J.G., Cooper, A., Dzamko, N. Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplexed single molecule counting. Sci. Rep., 13: 5217. doi: 10.1038/s41598-023-32480-0